Recomendaciones basadas en evidencia para el tratamiento preventivo de la migraña crónica. Asociación Colombiana de Neurología
DOI:
https://doi.org/10.22379/anc.2076Palabras clave:
CGRP, atogepant, topiramato, onabotulinumtoxina A, 3 cefalea y parestesia, cefalea, carga sintomática, calidad de vida, antagonistas del receptor del péptido relacionado con el gen de la calcitonina, amitriptilina, flunarizina, divalproato de sodioResumen
Introducción: debido al impacto en la calidad de vida de las personas que la padecen y la carga a los sistemas de salud, la migraña crónica es una condición clínica de importancia en la población general.
Objetivo: presentar recomendaciones basadas en evidencia, dirigidas a las intervenciones preventivas de la migraña crónica.
Metodología: revisión sistemática de la literatura, dirigida al tratamiento de pacientes adultos con migraña crónica.
Resultados: los medicamentos topiramato, amitriptilina, flunarizina y divalproato de sodio/ácido valproico se incluyeron en el grupo de opciones de primera línea. Las opciones consideradas como alternativas de segunda línea fueron onabotulinumtoxinA (ONABOT A), galcanezumab y atogepant.
Conclusión: se presentan las recomendaciones para el tratamiento de la migraña crónica, basadas en la evidencia disponible en la literatura, calificadas con el sistema GRADE.
Biografía del autor/a
Joe Muñoz-Cerón, Hospital Universitario Mayor Méderi, Bogotá, Colombia
Clínica Universitaria Colombia-Keralty, Bogotá, Colombia
Sergio Ramírez García, Fundación Universitaria Ciencias de la Salud, Bogotá, Colombia
Clínica Reina Sofia, Bogotá, Colombia
Claudia Marcela Moreno Rodríguez, Clínica Universitaria Colombia-Keralty, Bogotá, Colombia
Hospital San José, Fundación Universitaria Ciencias de la Salud, Bogotá, Colombia
José David Martínez Gaviria, Neuromédica, Medellín, Colombia
Clínica Universitaria Bolivariana, Medellín, Colombia
Referencias bibliográficas
Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211. https://doi.org/10.1177/0333102417738202
Cohen F, Brooks CV, Sun D, Buse DC, Reed ML, Fanning KM, et al. Prevalence and burden of migraine in the United States: a systematic review. Headache. 2024;64(5):516-32. https://doi.org/10.1111/head.14709
Lisicki M, Muñoz-Cerón J, Machado Sarmento E, Ribeiro AP, de Assis Dantas AC, Lara do Prado L, et al. Pan-American migraine prevalence: findings from the Americas’ migraine observatory study (AMIGOS). Cephalalgia. 2026;46(3):3331024261420837. https://doi.org/10.1177/03331024261420837
Rueda-Sánchez M, Díaz-Martínez LA. Prevalence and associated factors for episodic and chronic daily headache in the Colombian population. Cephalalgia. 2008;28(3):216-25. https://doi.org/10.1111/j.1468-2982.2007.01499.x
Díaz-Insa S, Santos-Lasaosa S, Driessen MT, Cohen JM, Lee L, Goadsby PJ. Burden of episodic and chronic migraine in patients who had failed multiple preventive treatments from France, Spain, and the United Kingdom. Acta Neurol Scand. 2024:4714514. https://doi.org/10.1155/ane/4714514
Buse DC, Silberstein SD, Manack AN, Papapetropoulos S, Lipton RB. Psychiatric comorbidities of episodic and chronic migraine. J Neurol. 2013;260(8):1960-9. https://doi.org/10.1007/s00415-012-6725-x
Constantinidis TS, Arvaniti C, Fakas N, Rudolf J, Kouremenos E, Giannouli E, et al. The prevalence and burden of medication overuse headache in Greece. Cephalalgia. 2023;43(6):3331024231184909. https://doi.org/10.1177/03331024231184909
Lipton RB, Lee L, Saikali NP, Bell J, Cohen JM. Effect of headache-free days on disability, productivity, quality of life, and costs among individuals with migraine. J Manag Care Spec Pharm. 2020;26(10):1344-52. https://doi.org/10.18553/jmcp.2020.20103
Muñoz-Cerón J, Gallo L, Gómez-Barrera D. The pillars of migraine diagnosis and treatment: Information from primary care physicians in Colombia. Neurol Perspect. 2025;5(3):100190. https://doi.org/10.1016/j.neurop.2025.100190
Cen J, Wang Q, Cheng L, Gao Q, Wang H, Sun F. Global, regional, and national burden and trends of migraine among women of childbearing age from 1990 to 2021: insights from the Global Burden of Disease Study 2021. J Headache Pain. 2024;25(1):96. https://doi.org/10.1186/s10194-024-01798-z
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https://doi.org/10.1136/bmj.n71
Otto CM, Abdullah AR, Davis LL, Ferrari VA, Fremes S, Mukherjee D, et al. 2025 ACC/AHA clinical practice guidelines core principles and development process: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation. 2025;152(18):e359-70. https://doi.org/10.1161/CIR.0000000000001383
Prasad M. Introduction to the GRADE tool for rating certainty in evidence and recommendations. Clin Epidemiol Glob Health. 2024;25:101484. https://doi.org/10.1016/j.cegh.2023.101484
Silberstein SD, Lipton RB, Dodick DW, Freitag FG, Ramadan N, Mathew N, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache. 2007;47(2):170-80. https://doi.org/10.1111/j.1526-4610.2006.00684.x
Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ, et al. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007;27(7):814-23. https://doi.org/10.1111/j.1468-2982.2007.01326.x
Yurekli VA, Akhan G, Kutluhan S, Uzar E, Koyuncuoglu HR, Gultekin F. The effect of sodium valproate on chronic daily headache and its subgroups. J Headache Pain. 2008;9(1):37-41. https://doi.org/10.1007/s10194-008-0002-5
Ebrahimi-Monfared M, Sharafkhah M, Abdolrazaghnejad A, Mohammadbeigi A, Faraji F. Use of melatonin versus valproic acid in prophylaxis of migraine patients: a double-blind randomized clinical trial. Restor Neurol Neurosci. 2017;35(4):385-93. https://doi.org/10.3233/rnn-160704
Blumenfeld AM, Schim JD, Chippendale TJ. Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine. Headache. 2008;48(2):210-20. https://doi.org/10.1111/j.1526-4610.2007.00949.x
Couch JR, Amitriptyline Versus Placebo Study Group. Amitriptyline in the prophylactic treatment of migraine and chronic daily headache. Headache. 2010;51(1):33-51. https://doi.org/10.1111/j.1526-4610.2010.01800.x
Magalhães E, Menezes C, Cardeal M, Melo A. Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine. Clin Neurol Neurosurg. 2010;112(6):463-6. https://doi.org/10.1016/j.clineuro.2010.02.004
Lai KL, Niddam DM, Fuh JL, Chen SP, Wang YF, Chen WT, et al. Flunarizine versus topiramate for chronic migraine prophylaxis: a randomized trial. Acta Neurol Scand. 2017;135(4):476-83. https://doi.org/10.1111/ane.12626
Gracia Naya M, Ríos C, García-Gomara MJ, Sánchez-Valiente S, Mauri-Llerda JA, Santos-Lasaosa S, et al. A comparative study of the effectiveness of topiramate and flunarizine in independent series of chronic migraine patients without medication abuse. Rev Neurol. 2013;57(8):347. https://doi.org/10.33588/rn.5708.2013241
Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30(7):793-803. https://doi.org/10.1177/0333102410364676
Diener HC, Dodick DW, Turkel CC, Demos G, Degryse RE, Earl NL, et al. Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine. Eur J Neurol. 2014;21(6):851-9. https://doi.org/10.1111/ene.12393
Silberstein SD, Diener HC, Dodick DW, Sommer K, Lipton RB. Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: an analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials. Headache. 2024;64(7):838-48. https://doi.org/10.1111/head.14743
Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):e2211-21. https://doi.org/10.1212/wnl.0000000000006640
Pozo-Rosich P, Detke HC, Wang S, Doležil D, Li LQ, Aurora SK, et al. Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study. Curr Med Res Opin. 2022;38(5):731-42. https://doi.org/10.1080/03007995.2022.2059975
Pozo-Rosich P, Ailani J, Ashina M, Goadsby PJ, Lipton RB, Reuter U, et al. Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402(10404):775-85. https://doi.org/10.1016/s0140-6736(23)01049-8
Goadsby PJ, Friedman DI, Holle-Lee D, Demarquay G, Ashina S, Sakai F, et al. Efficacy of atogepant in chronic migraine with and without acute medication overuse in the randomized, double-blind, phase 3 PROGRESS trial. Neurology. 2024;103(2):e209584. https://doi.org/10.1212/wnl.0000000000209584
Brandes JL. Practical use of topiramate for migraine prevention. Headache. 2005;45(supl. 1):S66-73. https://doi.org/10.1111/j.1526-4610.2005.4501007.x
Lipton RB, Silberstein S, Dodick D, Cady R, Freitag F, Mathew N, et al. Topiramate intervention to prevent transformation of episodic migraine: the topiramate INTREPID study. Cephalalgia. 2011;31(1):18-30. https://doi.org/10.1177/0333102410372427
Takeshima T, Suzuki N, Matsumori Y, Shimmoto N, Kurihara Y, Gunji R, et al. Effectiveness and safety of an extended-release tablet of sodium valproate for the prophylactic treatment of migraine: postmarketing surveillance in Japan. Neurol Clin Neurosci. 2016;4(4):134-41. https://doi.org/10.1111/ncn3.12053
Cui XY, Sun DM, Liu J, Wu QY, Zhang JF, Li X. The efficacy and safety of valproate medications for migraine in adults: a meta-analysis. Eur Rev Med Pharmacol Sci. 2020;24(10):5734-41. http://dx.doi.org/10.26355/eurrev_202005_21365
Doyle Strauss L, Weizenbaum E, Loder EW, Rizzoli PB. Amitriptyline dose and treatment outcomes in specialty headache practice: a retrospective cohort study. Headache. 2016;56(10):1626-34. https://doi.org/10.1111/head.12987
Berilgen MS, Bulut S, Gonen M, Tekatas A, Dag E, Mungen B. Comparison of the effects of amitriptyline and flunarizine on weight gain and serum leptin, C peptide and insulin levels when used as migraine preventive treatment. Cephalalgia. 2005;25(11):1048-53. https://doi.org/10.1111/j.1468-2982.2005.00956.x
Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007;151(6):737-48. https://doi.org/10.1038/sj.bjp.0707253
Miguel R, Correia ASA, Bugalho P. Iatrogenic parkinsonism: the role of flunarizine and cinnarizine. J Parkinsons Dis. 2014;4(4):645-9. https://doi.org/10.3233/jpd-140414
Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30(7):804-14. https://doi.org/10.1177/0333102410364677
Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50(6):921-36. https://doi.org/10.1111/j.1526-4610.2010.01678.x
Lanteri-Minet M, Ducros A, Francois C, Olewinska E, Nikodem M, Dupont-Benjamin L. Effectiveness of onabotulinumtoxinA (BOTOX®) for the preventive treatment of chronic migraine: a meta-analysis on 10 years of real-world data. Cephalalgia. 2022;42(14):1543-64. https://doi.org/10.1177/03331024221123058
Sarchielli P, Romoli M, Corbelli I, Bernetti L, Verzina A, Brahimi E, et al. Stopping onabotulinum treatment after the first two cycles might not be justified: Results of a real-life monocentric prospective study in chronic migraine. Front Neurol. 2017;8:655. https://doi.org/10.3389/fneur.2017.00655
Vernieri F, Paolucci M, Altamura C, Pasqualetti P, Mastrangelo V, Pierangeli G, et al. Onabotulinumtoxin-A in chronic migraine: should timing and definition of non-responder status be revised? Suggestions from a real-life Italian multicenter experience. Headache. 2019;59(8):1300-9. https://doi.org/10.1111/head.13617
Negro A, Curto M, Lionetto L, Martelletti P. A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience. J Headache Pain. 2015;17:1. https://doi.org/10.1186/s10194-016-0591-3
Khan FA, Mohammed AE, Poongkunran M, Chimakurthy A, Pepper M. Wearing off effect of OnabotulinumtoxinA near the end of treatment cycle for chronic migraine: a 4-year clinical experience. Headache. 2020;60(2):430-40. https://doi.org/10.1111/head.13713
Lu J, Zhang Q, Guo X, Liu W, Xu C, Hu X, et al. Calcitonin gene-related peptide monoclonal antibody versus botulinum toxin for the preventive treatment of chronic migraine: evidence from indirect treatment comparison. Front Pharmacol. 2021;12:631204. https://doi.org/10.3389/fphar.2021.631204
Wang YF, Yang FC, Chen LA, Chang TY, Su HC, Yang CP, et al. Comparative effectiveness and tolerability of calcitonin gene-related peptide (CGRP) monoclonal antibodies and onabotulinumtoxinA in chronic migraine: a multicenter, real-world study in Taiwan. Eur J Neurol. 2024;31(9):e16372. https://doi.org/10.1111/ene.16372
Melo-Carrillo A, Strassman AM, Nir RR, Schain AJ, Noseda R, Stratton J, et al. Fremanezumab-A humanized monoclonal anti-CGRP antibody-inhibits thinly myelinated (Aδ) but not unmyelinated (C) meningeal nociceptors. J Neurosci. 2017;37(44):10587-96. https://doi.org/10.1523/jneurosci.2211-17.2017
Argyriou AA, Dermitzakis EV, Xiromerisiou G, Vikelis M. OnabotulinumtoxinA add-on to monoclonal anti-CGRP antibodies in treatment-refractory chronic migraine. Toxins. 2022;14(12):847. https://doi.org/10.3390/toxins14120847
Blumenfeld AM, Frishberg BM, Schim JD, Iannone A, Schneider G, Yedigarova L, et al. Real-world evidence for control of chronic migraine patients receiving CGRP monoclonal antibody therapy added to OnabotulinumtoxinA: a retrospective chart review. Pain Ther. 2021;10(2):809-26. https://doi.org/10.1007/s40122-021-00264-x
Singh A, Balasundaram MK. Atogepant for migraine prevention: a systematic review of efficacy and safety. Clin Drug Investig. 2022;42(4):301-8. https://doi.org/10.1007/s40261-022-01130-0
Barbanti P, Egeo G, Pistoia F, Aurilia C, Scatena P, Rinalduzzi S, et al. GIANT: a prospective, multicenter, real-world study on the effectiveness, safety, and tolerability of atogepant in migraine patients with multiple therapeutic failures. J Headache Pain. 2025;26(1):122. https://doi.org/10.1186/s10194-025-02068-2
Ankrom W, Xu J, Vallee MH, Dockendorf MF, Armas D, Boinpally R, et al. Atogepant has no clinically relevant effects on the pharmacokinetics of an ethinyl estradiol/levonorgestrel oral contraceptive in healthy female participants. J Clin Pharmacol. 2020;60(9):1157-65. https://doi.org/10.1002/jcph.1610
Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A, American Headache Society. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American Headache Society position statement update. Headache. 2024;64(4):333-41. https://doi.org/10.1111/head.14692
Cómo citar
Publicado
Número
Sección
Licencia
Derechos de autor 2026 Asociación Colombiana de Neurología

Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Los autores renuncian al control y a los derechos de publicación de manuscritos, cediendo a Acta Neurológica Colombiana sus derechos, incluyendo la publicación en Internet y en medios magnéticos.
Todos los derechos incluidos en Acta Neurológica Colombiana están protegidos por derechos de autor. Conforme a la ley, esta prohibida su reproducción por cualquier medio mecánico o electrónico, sin permiso escrito del autor y los editores.
La responsabilidad de los conceptos que se publiquen es íntegramente del autor, y Acta Neurológica Colombiana no asume ninguna por ellos.
| Estadísticas de artículo | |
|---|---|
| Vistas de resúmenes | 15 |
| Vistas de PDF | 2 |
| Descargas de PDF | 2 |
| Vistas de HTML | 0 |
| Otras vistas | 0 |













